Unknown

Dataset Information

0

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.


ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) consists of at least 2 phenotypic subtypes; that is, the germinal center B-cell-like (GCB-DLBCL) and the activated B-cell-like (ABC-DLBCL) groups. It has been shown that GCB-DLBCL responds favorably to chemotherapy and expresses high levels of BCL6, a transcription repressor known to play a causative role in lymphomagenesis. In comparison, ABC-DLBCL has lower levels of BCL6, constitutively activated nuclear factor-kappaB, and tends to be refractory to chemotherapy. Here, we report that the STAT3 gene is a transcriptional target of BCL6. As a result, high-level STAT3 expression and activation are preferentially detected in ABC-DLBCL and BCL6-negative normal germinal center B cells. Most importantly, inactivating STAT3 by either AG490 or small interference RNA in ABC-DLBCL cells inhibits cell proliferation and triggers apoptosis. These phenotypes are accompanied by decreased expression of several known STAT3 target genes, including c-Myc, JunB, and Mcl-1, and increased expression of the cell- cycle inhibitor p27. In addition to identifying STAT3 as a novel BCL6 target gene, our results define a second oncogenic pathway, STAT3 activation, which operates in ABC-DLBCL, suggesting that STAT3 may be a new therapeutic target in these aggressive lymphomas.

SUBMITTER: Ding BB 

PROVIDER: S-EPMC2214773 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Ding B Belinda BB   Yu J Jessica JJ   Yu Raymond Y-L RY   Mendez Lourdes M LM   Shaknovich Rita R   Zhang Yonghui Y   Cattoretti Giorgio G   Ye B Hilda BH  

Blood 20071019 3


Diffuse large B-cell lymphoma (DLBCL) consists of at least 2 phenotypic subtypes; that is, the germinal center B-cell-like (GCB-DLBCL) and the activated B-cell-like (ABC-DLBCL) groups. It has been shown that GCB-DLBCL responds favorably to chemotherapy and expresses high levels of BCL6, a transcription repressor known to play a causative role in lymphomagenesis. In comparison, ABC-DLBCL has lower levels of BCL6, constitutively activated nuclear factor-kappaB, and tends to be refractory to chemot  ...[more]

Similar Datasets

| S-EPMC6135800 | biostudies-literature
| S-EPMC2938343 | biostudies-literature
| S-EPMC3390034 | biostudies-literature
2006-12-08 | GSE3892 | GEO
| S-EPMC4411286 | biostudies-literature
| S-EPMC4542576 | biostudies-literature
2017-05-15 | E-MTAB-4495 | biostudies-arrayexpress
2017-05-15 | E-MTAB-4497 | biostudies-arrayexpress
| S-EPMC4747717 | biostudies-literature
| S-EPMC4728674 | biostudies-literature